Brief: Pulmatrix Announces Patient Dosing Completed For Its Novel Inhaled Therapy Pur3100 For Acute Migraine
26/09/2022 14:53
Sept 26 (Reuters) - Pulmatrix Inc PULM.O :
* PULMATRIX ANNOUNCES PATIENT DOSING COMPLETED FOR ITS NOVEL
INHALED THERAPY PUR3100 FOR ACUTE MIGRAINE
* PULMATRIX INC - EXPECTS PHARMACOKINETIC DATA FROM PHASE 1
STUDY
IN Q4 2022
Source text for Eikon: ID:nPn1YBNQ5a
Further company coverage: PULM.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Pulmatrix
See all newsBrief: Pulmatrix Announces Second Quarter 2026 Financial Results And Progress On Merger
Pulmatrix Q2 loss narrows on clinical development hold
Pulmatrix Q1 net loss narrows, clinical development on hold
Brief: Pulmatrix Announces Closing Of Preferred Stock Transaction As Part Of Planned Merger
NASDAQ RESUMED AT 09:00 AM